These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 10680279)

  • 21. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
    Lincoff AM; Califf RM; Topol EJ
    J Am Coll Cardiol; 2000 Apr; 35(5):1103-15. PubMed ID: 10758948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction.
    Hudson MP; Greenbaum AB; Harrington RA; Ohman EM
    J Thromb Thrombolysis; 1999 Jun; 7(3):241-5. PubMed ID: 10373717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Glycoprotein IIb/IIIa inhibitors in unstable angina].
    Boughalem K; Pagny JY; Demichéli T; Danchin N
    Ann Cardiol Angeiol (Paris); 2001; 50(7-8):377-84. PubMed ID: 12555630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
    Gibson CM; Moynihan JL; Al-Mousa EN; Campsey M; Gandhi R; Murphy S; Mattson S; Ryan KA; Mesley R; Swanson J; Arshad MN; Marble SJ
    J Thromb Thrombolysis; 1999 Jun; 7(3):287-302. PubMed ID: 10375390
    [No Abstract]   [Full Text] [Related]  

  • 25. [New thrombocyte aggregation inhibitor in therapy of unstable angina].
    Hamm C
    Z Kardiol; 2000 Nov; 89(11):1053-6. PubMed ID: 11149273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelet glycoprotein IIb/IIIa receptor blockers: An appropriate-use model for expediting care in acute coronary syndromes.
    Kereiakes DJ; McDonald M; Broderick T; Roth EM; Whang DD; Martin LH; Howard WL; Schneider J; Shimshak T; Abbottsmith CW
    Am Heart J; 2000 Feb; 139(2 Pt 2):S53-60. PubMed ID: 10650317
    [No Abstract]   [Full Text] [Related]  

  • 27. Gene mutations of platelet glycoproteins and response to tirofiban in acute coronary syndrome.
    Mansur Ade P; Roggerio A; Takada JY; Caribé PM; Avakian SD; Strunz CM
    Sao Paulo Med J; 2016 Jan; 134(3):199-204. PubMed ID: 26786608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycoprotein IIb/IIIa inhibitors.
    Stevens M
    Intensive Crit Care Nurs; 2002 Feb; 18(1):64-6. PubMed ID: 12008879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes.
    Jennings LK
    Expert Opin Drug Metab Toxicol; 2005 Dec; 1(4):727-37. PubMed ID: 16863436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization.
    Lincoff AM
    Am J Cardiol; 1998 Oct; 82(8B):36P-42P. PubMed ID: 9809890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IIb's are not IIb's.
    Kereiakes DJ; Runyon JP; Broderick TM; Shimshak TM
    Am J Cardiol; 2000 Apr; 85(8A):23C-31C. PubMed ID: 10793177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Redefining medical treatment in the management of unstable angina.
    Braunwald E; Califf RM; Cannon CP; Fox KA; Fuster V; Gibler WB; Harrington RA; King SB; Kleiman NS; Theroux P; Topol EJ; Van de Werf F; White HD; Willerson JT
    Am J Med; 2000 Jan; 108(1):41-53. PubMed ID: 11059440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
    McCollam PL; Foster DA; Riesmeyer JS
    Am J Health Syst Pharm; 2003 Jun; 60(12):1251-6. PubMed ID: 12845921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platelet glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction.
    Bates ER
    Curr Opin Cardiol; 1998 Jul; 13(4):274-9. PubMed ID: 10091023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators.
    Zhao XQ; Théroux P; Snapinn SM; Sax FL
    Circulation; 1999 Oct; 100(15):1609-15. PubMed ID: 10517731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
    Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
    N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GP IIb/IIIa inhibitors: an evidence-based approach to their use.
    Med Manag Netw; 1999 Mar; 7(3):5-9. PubMed ID: 10346546
    [No Abstract]   [Full Text] [Related]  

  • 38. Therapeutics of platelet glycoprotein IIb/IIIa receptor antagonism.
    Gowda RM; Khan IA; Vasavada BC; Sacchi TJ
    Am J Ther; 2004; 11(4):302-7. PubMed ID: 15266223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.
    Kimmelstiel C; Phang R; Rehman A; Rand W; Miele R; Rhofiry J; MacIsaac DA; Gouveia W; Denier D; Becker RC
    J Thromb Thrombolysis; 2001 May; 11(3):203-9. PubMed ID: 11577258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [GPIIb-IIIa inhibitors].
    Nurden P
    Transfus Clin Biol; 2001 Apr; 8(2):114-22. PubMed ID: 11386043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.